4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities (2019 - 2026)
4D Molecular Therapeutics (FDMT) reported Other Non-Current Liabilities of $121000.0 for Q1 2026, down 31.64% year-over-year from $177000.0 in Q1 2025, and down 12.32% quarter-over-quarter from $138000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 8 years of Other Non-Current Liabilities data on file, last reported at $121000.0 in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $121000.0, down 31.64% year-over-year; the trailing twelve-month figure through Mar 2026 was $121000.0 (down 31.64% YoY), and the FY2025 annual result was $138000.0, down 66.34% from the prior year.
- Other Non-Current Liabilities slipped to $121000.0 in Q1 2026 per FDMT's latest filing, from $138000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $410000.0 in Q4 2024 and troughed at $12000.0 in Q2 2022.
- A 5-year average of $151470.6 and a median of $161000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities sank 98.93% in 2022, then soared 1080.95% in 2023.
- A 5-year view of Other Non-Current Liabilities shows it stood at $21000.0 in 2022, then soared by 1080.95% to $248000.0 in 2023, then surged by 65.32% to $410000.0 in 2024, then plunged by 66.34% to $138000.0 in 2025, then dropped by 12.32% to $121000.0 in 2026.
- Business Quant data shows FDMT's Other Non-Current Liabilities at $121000.0 in Q1 2026, $138000.0 in Q4 2025, and $345000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 121,000.00 |
| Dec 31, 2025 | 138,000.00 |
| Sep 30, 2025 | 345,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 177,000.00 |
| Dec 31, 2024 | 410,000.00 |
| Sep 30, 2024 | 196,000.00 |
| Jun 30, 2024 | 214,000.00 |
| Mar 31, 2024 | 231,000.00 |
| Dec 31, 2023 | 248,000.00 |
| Sep 30, 2023 | 20,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Dec 31, 2022 | 21,000.00 |
| Sep 30, 2022 | 213,000.00 |
| Jun 30, 2022 | 12,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | 214,000.00 |
| Sep 30, 2021 | 544,000.00 |
| Jun 30, 2021 | 207,000.00 |